Peer-reviewed veterinary case report
New liposome mix improves visceral leishmaniasis treatment in dogs
By Azevedo, Erly G et al.·Published in Expert opinion on drug delivery·2014·Universidade Federal de Minas Gerais, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
- Species:
- dog
Plain-English summary
A group of mongrel dogs infected with Leishmania infantum, which causes visceral leishmaniasis, were treated with a new type of medication that combines two different liposome formulations. This mixed treatment was found to be more effective at targeting the infection in the bone marrow compared to traditional treatments. The results showed a significant reduction in the parasite load in both the bone marrow and spleen of the dogs. This promising approach could lead to better treatment options for dogs suffering from this serious disease.
People also search for: dog leishmaniasis treatment · visceral leishmaniasis in dogs · Leishmania infection in dogs
Abstract
OBJECTIVE: Test the hypothesis that pegylated meglumine antimoniate-containing liposomes (LMA) and their mixture with non-pegylated (conventional) LMA may be more effective than conventional LMA against visceral leishmaniasis (VL), because of wider drug distribution among different mononuclear phagocyte system (MPS) tissues. METHODS: Sb was determined in the blood and MPS tissues after administration of pegylated or conventional LMA intravenously to mongrel dogs naturally infected with Leishmania infantum and Swiss mice. Pegylated and conventional LMA as well as their mixture were evaluated for their antileishmanial efficacy in BALB/c infected with L. infantum through determination of parasite load in liver, spleen and bone marrow. RESULTS: An improved targeting of Sb to the bone marrow of dogs was clearly evidenced, as an important impact of pegylation. In accordance with this data, pegylated LMA significantly reduced parasite load in bone marrow of infected mice, in contrast to conventional LMA. The mixed formulation of conventional and pegylated LMA promoted parasite suppression to a higher extent in both spleen and bone marrow, compared to pegylated or conventional LMA. CONCLUSIONS: The present work establishes for the first time the potential of mixed formulations of conventional and pegylated liposomes as a drug delivery strategy for improved treatment of VL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24962630/